Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Taking AIM at Breast Cancer: Targeting Adiposity and Inflammation With Movement to Improve Prognosis in Breast Cancer Survivors

NCT04720209 is registered in ClinicalTrials.gov with Dana-Farber Cancer Institute as lead sponsor.

NCT NCT04720209
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04720209 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Taking AIM at Breast Cancer: Targeting Adiposity and Inflammation With Movement to Improve Prognosis in Breast Cancer Survivors
Lead sponsor
Dana-Farber Cancer Institute
Phase
Not applicable
Overall status
Active, not recruiting
Start date
August 13, 2021
Completion date
December 31, 2028
Enrollment
102 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, breast cancer stage i, breast cancer stage ii, breast cancer stage iii